NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (“ROTH”), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that Jotin Marango, M.D., Ph.D. and Yasmeen Rahimi, Ph.D. have joined the firm’s healthcare research team.
Dr. Marango is a Managing Director and Senior Research Analyst covering biotechnology and therapeutics. He joins ROTH from H.C. Wainwright & Co., where he covered hematology, oncology, and pulmonary therapeutics, with a particular focus on epigenetic and molecularly targeted therapies. Dr. Marango began his career in equity research with Collins Stewart/Canaccord Genuity. Previously, Dr. Marango served as Chief Operating Officer at the Samuel Waxman Cancer Research Foundation, where he oversaw academic collaborations in translational therapeutics, as well as venture philanthropy initiatives in drug development. Dr. Marango studied theoretical chemistry and classical literature at Harvard University, and later received his M.D. and Ph.D. degrees from the Mount Sinai School of Medicine in New York.
Dr. Rahimi is a Director and Research Analyst covering biotechnology and therapeutics, with particular interest in nonalcoholic fatty liver disease (NASH), metabolic and rare diseases. She joins ROTH from H.C. Wainwright & Co., and prior to that, she was a research associate at Guggenheim Securities. Dr. Rahimi also worked as a research scientist at Shire Pharmaceuticals where she developed biomarker strategies for a number of clinical programs. She trained at Yale University in the laboratory of Dr. Gerald Shulman, who pioneered the understanding of lipid-induced insulin resistance contributing to the pathogenesis of fatty liver disease. Dr. Rahimi earned her Ph.D. in Biochemistry from Indiana University School of Medicine. In addition, she has an M.S. in Bioanalytical Chemistry from Purdue University, and a joint B.A. in German and Chemistry from Butler University.
Jeff Martin, Director of Research, commented, “Over the course of nearly a decade, ROTH has established a strong foundation in the healthcare sector, and it remains a key focus for the firm. I am particularly pleased to welcome Dr. Marango and Dr. Rahimi to the team. I anticipate their deep domain expertise in a broad spectrum of therapeutic areas will prove valuable in identifying biotechnology stocks with strong near-and long-term prospects.”
Dr. Marango commented, “This is a very exciting time in biotechnology and therapeutics, for patients, physicians, drug developers, and investors alike. Together with the greater ROTH team, we will leverage our fundamental approach and scientific acumen to provide high quality research, focused on biotechnology programs and companies with the deepest impact and greatest value inflection.” Dr. Rahimi added, “I am excited to join the high caliber analysts at ROTH, a firm that signifies a solid presence in the healthcare sector.”
“We are pleased to have Jotin and Yasmeen join our healthcare research team,” said Byron Roth, CEO of ROTH Capital Partners. “Coupled with the recent additions to our healthcare banking team, the academic and private sector backgrounds of Drs. Marango and Rahimi provide us with the additional resources and expertise to enhance our position as one of the leading investment banks for emerging healthcare companies and their investors.”
About Roth Capital Partners, LLC:
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, Calif., ROTH is privately-held and owned by its employees, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.